Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
T. Hishiki, T. Morita, D. Akazawa…·K. Watashi
This study identifies IMPDH as a potential target for anti-monkeypox virus agents by showing that compounds targeting this enzyme inhibit MPXV replication more effectively than existing treatments.
D. Akazawa, H. Ohashi, T. Hishiki…·K. Watashi
This study identifies atovaquone, mefloquine, and molnupiravir as potential anti-monkeypox virus drugs, with atovaquone showing enhanced efficacy when combined with tecovirimat.
N. M. Schmidt, P. A. Wing, R. Peters…·J. A. McKeating
This paper shows that ACAT inhibitors like Avasimibe reduce SARS-CoV-2 replication and enhance antiviral T cell activity in patients.
H. Ohashi, T. Hishiki, D. Akazawa…·K. Watashi
The paper compares the efficacy of neutralizing antibodies and antiviral drugs against SARS-CoV-2 Omicron subvariants BA.1 and BA.2, finding differential responses to specific treatments.
K. Shionoya, M. Yamasaki, S. Iwanami…·K. Watashi
This study identifies Mefloquine as a potent in vitro entry inhibitor of SARS-CoV-2 with higher antiviral activity than Hydroxychloroquine.
H. Ohashi, K. Watashi, W. Saso…·T. Wakita
This study identifies a new multidrug combination treatment for COVID-19 using nelfinavir and cepharanthine, showing synergistic antiviral effects and improved disease control.